04:11 , Dec 8, 2017 |  BC Week In Review  |  Company News

Skyline, Helomics, GLG partner for ovarian and breast cancer

GLG Pharma LLC (Jupiter, Fla.), Skyline Medical Inc. (NASDAQ:SKLN) and Helomics Corp. (Pittsburgh, Pa.) partnered to develop therapeutics and diagnostics for ovarian and breast cancer patients, especially those who present with ascites fluid. The companies...
08:00 , Mar 3, 2014 |  BC Week In Review  |  Clinical News

ChemoFx Assay diagnostic data

An observational study in 276 patients with stage III/IV ovarian, fallopian or peritoneal cancer who received first-line therapy of carboplatin and paclitaxel showed that median PFS was significantly lower in patients classified as platinum-resistant by...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Clinical News

ChemoFx Assay diagnostic data

Additional data from a blinded, 9-year observational study in 262 patients with recurrent ovarian cancer showed that patients treated with a chemotherapeutic agent identified to be responsive by Precision Therapeutics' ChemoFx Assay had a significant...
07:00 , Mar 18, 2013 |  BC Week In Review  |  Clinical News

ChemoFx Assay diagnostic data

Top-line data from a blinded, 9-year observational study in 262 patients with recurrent ovarian cancer showed that patients treated with a chemotherapeutic agent identified to be responsive by Precision Therapeutics' ChemoFx Assay had a significant...
07:00 , Jun 22, 2009 |  BC Week In Review  |  Clinical News

ChemoFx Assay diagnostic data

Data from 405 samples of endometrial carcinoma showed that in vitro response rates predicted by ChemoFx were similar to published response rates for all chemotherapy treatments, except for single-agent carboplatin. Data were presented at the...
07:00 , Jun 22, 2009 |  BC Week In Review  |  Clinical News

ChemoFx Assay diagnostic data

In a study of 54 primary colorectal cancer cell cultures, ChemoFx predicted that 8% of the cultures would be responsive to Erbitux cetuximab, 22% would have an intermediate response and 70% would be non-responsive. The...
07:00 , Jul 7, 2008 |  BC Week In Review  |  Clinical News

ChemoFx Assay: Phase II data

Precision published data showing that its ChemoFx Assay correctly predicted response to therapy 75% of the time in tissue samples from a subset of 34 patients who were enrolled in the previously completed Phase II...